Skip to main content
. Author manuscript; available in PMC: 2014 Feb 13.
Published in final edited form as: Leukemia. 2008 Nov 13;23(3):449–456. doi: 10.1038/leu.2008.325

Table 2.

Efficacy of regimens used as frontline treatment in multiple myeloma

Therapy No. of patients ≥PR (%) ≥VGPR (%) Progression-free survival Overall survival References
Transplant candidates
 Thal/Dex 235 63 43.8 14.9 months 68% @ 2 years 24
 ASCT-T 323 ND ND 56% @ 5 years 65% @ 5 years 25
 Rev/Dex 34 91 38 74% @ 2 years 91% @ 2 years 28
 BiRD 72 90 73 75% @ 2 years ND 31
 Bort/Dex 52 66 31 ND ND 32
 PAD 65 97.1 50 83% @ 2 years 92% @ 2 years 36
Non-transplant candidates
 MPT 129 76 36 54% @ 2 years 80% @ 3 years 45
 MPT 125 76 47 27.5 months 51.6 months 43
 MPR 54 81 47 80% @ 2 years 91% @ 2 years 48
 MPV 60 89 ND 65% @ 2 years 86% @ 2 years 49

Abbreviations: ASCT-T, autologous stem cell transplantation+thalidomide; BiRD, biaxin+lenalidomide+dexamethasone; Bort/Dex, bortezomib+-dexamethasone; MPR, melphalan+prednisone+lenalidomide; MPT, melphalan+prednisone+thalidomide; MPV, melphalan+prednisone+bortezomib; ND, not determined; PAD, bortezomib+pegylated-lyposomal-doxorubicin+dexamethasone; PR, partial response; Rev/Dex, lenalidomide+dexamethasone; Thal/Dex, thalidomide+dexamethasone; VGPR, very good partial response; VTD, bortezomib+thalidomide+dexamethasone.